PetVivo Holdings AI Stock Analysis
Want to see PETV full AI Analyst Report?
PetVivo Holdings (PETV) AI Stock Analysis
PetVivo Holdings
(Other OTC:PETV)
The score is held down primarily by weak financial performance (large losses, significant cash burn, and equity pressure) and bearish technicals (below major moving averages with negative MACD). The earnings call shows operational improvement and strong margins, but near-term liquidity and reliance on financing materially temper the outlook; valuation is also constrained by negative earnings.
PetVivo Holdings (PETV) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $21.28M
- Dividend Yield
- ―
- Average Volume (3M)
- 13.47K
- Price to Earnings (P/E)
- -1.8
- Beta (1Y)
- 0.26
- Revenue Growth
- -9.54%
- EPS Growth
- 18.63%
- Country
- US
- Employees
- 22
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
PetVivo Holdings Business Overview & Revenue Model
Company Description
PetVivo Holdings, Inc. operates as a biomedical technology firm, specializing in the invention, commercialization, and licensing of advanced medical devices and biomaterials intended to treat a variety of ailments and diseases affecting animals. Its...
How the Company Makes Money
PetVivo primarily makes money by selling its companion-animal joint health product(s) to the veterinary market. Revenue is generated from product sales made through veterinary channels (e.g., veterinary clinics and/or distribution partners) where vet...
PetVivo Holdings Earnings Call Summary
The call communicated meaningful commercial, product and technological progress — including double-digit revenue growth, margin improvement, international regulatory recognition, strong AI beta results, and strategic M&A and partnership activity. However, the company remains small in absolute revenue, continues to report operating and net losses, has a tight cash balance ($123k) and depends on pending financing and grants (including a referenced $5M raise to close the PBM acquisition). The positives around product validation, high-margin pipeline opportunities and operational improvements are balanced by liquidity, financing and execution risks.
Q1-2027 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided continued momentum for fiscal 2027, highlighting Q1 revenue up 13% YoY to $338K (up 33% sequentially) — $276K via distributors and $62K direct — with gross profit $223K (66% margin) and flagship Spryng margin ~90.3%; total operating expenses declined 10% to $1.8M (R&D -31%, G&A -9%, S&M +2%) producing an operating loss of $1.6M and a net loss of $1.7M ($0.05/share), an ~30% improvement from $2.3M ($0.10) a year ago. Cash used in operations fell ~40% to ~$966K (a $668K reduction), ending cash was $123K, and management expects completion of a $1.35M subscription commitment and has discussed a ~$5M capital raise tied to the PBM acquisition (expected to close soon). They forecast higher revenue margins going forward, Health Canada commercialization with Canadian distributors anticipated in 1–2 months, a government grant decision before year‑end, PetVivo.ai commercial launch in the coming months after beta results showing a 50–90% reduction in customer acquisition cost (from $80–$400 to <$43) and 97% diagnostic accuracy, and a new recurring PetVivo.ai revenue stream with projected 80–90% gross margins.
PetVivo Holdings Financial Statement Overview
Summary
Financials are dominated by very weak profitability and heavy cash burn (TTM operating/free cash flow about -$5.4M vs. ~$1.18M revenue). Gross margin is strong (~67%) and losses have narrowed, and leverage is not excessive (debt-to-equity ~0.38), but declining equity and ongoing large losses keep overall financial strength low.
Income Statement
22NegativeBalance Sheet
41NeutralCash Flow
18Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.18M | 1.14M | 1.13M | 968.71K | 917.16K | 115.59K |
| Gross Profit | 791.34K | 754.75K | 994.86K | 739.53K | 390.35K | -85.57K |
| EBITDA | -8.27M | -8.86M | -7.69M | -10.49M | -8.62M | -4.99M |
| Net Income | -9.78M | -10.47M | -8.40M | -10.96M | -8.70M | -4.94M |
Balance Sheet | ||||||
| Total Assets | 2.67M | 3.58M | 9.34M | 3.12M | 2.44M | 7.43M |
| Cash, Cash Equivalents and Short-Term Investments | 122.63K | 350.78K | 377.69K | 87.40K | 475.31K | 6.11M |
| Total Debt | 515.11K | 376.16K | 2.90M | 1.37M | 345.33K | 332.85K |
| Total Liabilities | 1.31M | 1.38M | 5.12M | 2.43M | 1.71M | 1.44M |
| Stockholders Equity | 1.36M | 2.20M | 4.22M | 685.95K | 725.02K | 5.99M |
Cash Flow | ||||||
| Free Cash Flow | -5.46M | -6.12M | -5.89M | -7.73M | -7.22M | -4.36M |
| Operating Cash Flow | -5.44M | -6.11M | -5.32M | -7.42M | -6.79M | -4.17M |
| Investing Cash Flow | -8,304 | 11.80K | -563.43K | -309.10K | -423.93K | -183.18K |
| Financing Cash Flow | 2.34M | 6.07M | 6.03M | 7.34M | 1.59M | 10.44M |
PetVivo Holdings Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PETV, the sentiment is Negative. The current price of 0.56 is below the 20-day moving average (MA) of 0.66, below the 50-day MA of 0.71, and below the 200-day MA of 0.75, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 33.99 is Neutral, neither overbought nor oversold. The STOCH value of 14.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PETV.
PetVivo Holdings Risk Analysis
PetVivo Holdings disclosed 35 risk factors in its most recent earnings report. PetVivo Holdings reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksPetVivo Holdings Peers Comparison
Overall Rating
BVS66Neutral
KIDS61Neutral
ANIK56Neutral
TELA48Neutral- PETV42Neutral
XTNT41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| BVS | 66Neutral | $942.04M | 12.98 | 27.23% | ― | 3.87% | 623.68% |
| KIDS | 61Neutral | $874.18M | -23.55 | -9.91% | ― | 16.15% | 27.21% |
| ANIK | 56Neutral | $180.43M | -107.72 | -1.28% | ― | 9.42% | 94.37% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TELA | 48Neutral | $36.11M | -1.27 | 425.91% | ― | 1.46% | 15.79% |
| PETV | 42Neutral | $21.18M | -1.79 | -351.76% | ― | -9.54% | 18.63% |
| XTNT | 41Neutral | $38.57M | -3.38 | -23.45% | ― | -14.27% | -132.84% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PETV | Petvivo Holdings Inc | 0.56 | -0.77 | -57.89% | |
| ANIK | Anika Therapeutics, Inc. | 13.95 | 3.96 | 39.64% | |
| XTNT | Xtant Medical Holdings Inc | 0.28 | -0.38 | -57.52% | |
| KIDS | Orthopediatrics Corp | 33.67 | 16.96 | 101.50% | |
| TELA | Tela Bio, Inc. | 0.94 | -0.06 | -5.90% | |
| BVS | Bioventus, Inc. | 10.99 | 3.64 | 49.52% |
PetVivo Holdings Corporate Events
PetVivo Holdings Announces Board Changes and New Director
PositiveOn September 22, 2026, PetVivo Holdings announced that life sciences executive Michael K. Handley joined its Board of Directors, filling the vacancy created by the same-day resignation of director Joseph Jasper, which the company said did not stem fr...
PetVivo Holdings Adds Veteran Leader to Board
PositiveOn September 22, 2026, PetVivo Holdings, Inc. announced that veterinarian and healthcare executive Jaime K. Pickett joined its Board of Directors, filling the vacancy created by the resignation of director Diane Levitan, whose departure was not due t...
PetVivo Holdings Updates Investor Presentation Under Regulation FD
NeutralPetVivo Holdings has furnished an investor presentation as part of a Form 8-K filing, outlining information it expects to use in upcoming appearances at investor conferences and other forums. The materials are being shared under SEC Regulation FD, si...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026